For example, Hugo reported that PD-1 blockade was more effective for BRCA2-mutant melanoma [30], but avelumab did not show a clinically meaningful effect for advanced ovarian carcinoma (JAVELIN Ovarian 100 trial), despite the fact that HRD is closely involved in the development of ovarian cancer [31]. Here, BRCA2 is linked to ovarian carcinoma.